Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

EGFR-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment for NSCLC. However, acquired drug resistance often occurs after with EGFR-TKIs. EGFR T790M and C797S mutations are most common mechanism in patients who failed from first- third- generation TKI treatments, respectively. there is no standard of care NSCLC harboring in-cis. The present case reports a 69-year-old Chinese man advanced exon 19-deletion, T790M, cis-C797S, HER2 amplification was heavily pre-treated. patient then given combination afatinib apatinib achieved PFS more than 10 months. This showed that plus may be promising therapy 19Del-T790M-cis-C797S mutant amplified